Background: Despite recommendations in the guidelines and consensus documents, there
has been no randomized controlled trial evaluating oral anticoagulation (OAC) alone without …

Background: Early outcomes of patients in the PRAGUE-18 (Comparison of Prasugrel and
Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any significant …

ContextThe benefit of clopidogrel pretreatment before percutaneous coronary intervention
(PCI) remains debated and its use has not been universally adopted. ObjectiveTo determine …

Aims The aim of this study was to determine whether clopidogrel plus aspirin provides
greater protection against major cardiovascular events than aspirin alone in patients with …

This article about currently available antiplatelet drugs is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …

Objectives: Our goal was to compare the safety and initial efficacy of AZD6140, the first
reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with …

Among patients with HF or evidence of LV dysfunction after acute MI enrolled in the Optimal
Trial in Myocardial Infarction With the Angiotensin II Antagonist Losartan (OPTIMAAL) …

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …

We use machine learning as a tool to study decision making, focusing specifically on how
physicians diagnose heart attack. An algorithmic model of a patient's probability of heart …

The 2010 AHA Guidelines for CPR and ECC for the evaluation and management of acute
coronary syndromes (ACS) are intended to define the scope of training for healthcare …